CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 160 target
Drug / intervention
SHR-A1811 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06649331
NCT06649331Phase 2RecruitingOn TrackUpdated 2mo ago
CompareCT.gov

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial

Fudan University·interventional·Posted Oct 18, 2024·Updated Apr 8, 2026

In Brief

A Phase 2 clinical trial evaluating SHR-A1811, SHR-A1921, and 6 other interventions for Advanced Breast Cancer and 4 related conditions. Currently recruiting, targeting 160 participants across 1 site.

Detailed Summary

This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
202520262027
First PostedOct 18, 2024
Enrollment StartOct 21, 2024
Primary CompletionSep 1, 2026
Study CompletionSep 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.7 years agoPrimary completion in 2 months

Interventions

SHR-A1811drug

A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

SHR-A1921drug

A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.

SHR-A2009drug

A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.

SHR-A2102drug

A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.

Famitinibdrug

A VEGFR inhibitor administered orally per the protocol.

Fat Module Formula for Special Medical Purposesdietary

This nutritional formulation is composed primarily of medium-chain triglycerides (MCT), which are metabolized by the liver to induce nutritional ketosis, thereby significantly elevating circulating levels of beta-hydroxybutyrate (BHB).

Trastuzumab (or biosimilar)drug

An anti-HER2 antibody, via intravenous (into the vein) infusion or subcutaneous per protocol.

9MW2821drug

A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.